MTOR and hepatocellular carcinoma: For the treatment of HCC, GNS561, a new lysosomotropic small molecule drug was developed to target PPT1 to modulate lysosomal deacidification and inhibit mammalian target of rapamycin (mTOR) signaling pathway.